UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

AMENDMENT NO. 1 TO

FORM 10-Q/A

 

 

(Mark One)

xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Quarterly Period Ended March 31, 2012

 

¨TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from to

 

Commission file number: 000-54402

 

 

BIORESTORATIVE THERAPIES, INC.

(Exact name of registrant as specified in its charter)

 

 

Nevada   91-1835664
(State or Other Jurisdiction of   (I.R.S. Employer
Incorporation or Organization)   Identification No.)

 

555 Heritage Drive    
Jupiter, Florida   33458
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (561) 904-6070

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer ¨   Accelerated filer ¨
         
Non-accelerated filer ¨ (Do not check if a smaller reporting company) Smaller reporting company x

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act): Yes ¨ No x

 

As of May 9, 2012, there were 655,491,911 shares of the registrant’s common stock outstanding.

 

 
 

 

EXPLANATORY NOTE

 

This amendment is being filed to correct the number of outstanding shares of the registrant as of May 9, 2012, as set forth on the cover page of the Form 10-Q, to exclude treasury shares from the calculation thereof.

 

 
 

 

PART II - OTHER INFORMATION

 

Item 6. Exhibits.

 

Exhibit   Description
31.1   Chief Executive Officer Certification *
31.2   Chief Financial Officer Certification *
32   Section 1350 Certification **
101.INS   XBRL Instance Document**
101.SCH   XBRL Schema Document **
101.CAL   XBRL Calculation Linkbase Document**
101.DEF   XBRL Definition Linkbase Document**
101.LAB   XBRL Label Linkbase Document**
101.PRE   XBRL Presentation Linkbase Document**

 

*   Filed herewith
**   Furnished herewith

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: June 1, 2012 BIORESTORATIVE THERAPIES, INC.
     
  By:  /s/ Mark Weinreb
    Mark Weinreb
    Chief Executive Officer
    (Principal Executive and Financial Officer)